2009•European Journal of NeurologyRequires access

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

Norman Putzki, Kiriaki Kollia, Susan L. Woods, Ezinne O. Igwe, H. C. Diener, Volker Limmroth

Abstract

BACKGROUND: Natalizumab has been recommended for the treatment of patients with relapsing remitting multiple sclerosis with insufficient response to interferon-beta (IFN-beta) or glatiramer acetate (GA). METHOD: Prospective, observational study. RESULTS: We found a reduction of the annualized relapse rate from 2.1 under IFN-beta or GA to 0.2 one year after switching to natalizumab. There were 94% fewer gadolinium enhancing lesions with natalizumab. CONCLUSION: Natalizumab reduced short term clinical and MRI activity in second line therapy and efficacy is comparable to first line therapy as demonstrated in the pivotal trials.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 49 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Natalizumab, Glatiramer acetate, Medicine, Multiple sclerosis, Relapsing remitting, Second-line therapy, Interferon beta, Internal medicine